The whole archive, filed by the part of life it belongs to — and labelled with how strong the evidence behind it actually is.
Showing 2041–2064 of 3,538
The **antibiotic resistance market** is projected to grow from **USD 9.28 billion in 2025** to **USD 12.72 billion by 2031**, reflecting a **CAGR of 5.40%** dur...
A new therapy for Hunter syndrome shows promise in treating neurological symptoms in children.
A new trial is testing a drug that may enhance insulin sensitivity for Type 2 diabetes.
A new gene delivery system may enhance cancer therapies by targeting immune cells safely.
Bioxodes SA has announced the final results of its Phase 2a BIRCH trial for **BIOX-101**, an investigational therapy targeting **intracerebral hemorrhage (ICH)*...
Boehringer Ingelheim has announced promising topline results from the Phase III **SYNCHRONIZE-1 trial**, which evaluated the efficacy of **survodutide** (BI 456...
A daily vitamin D supplement may improve chemotherapy outcomes for women with breast cancer.
Santhera Pharmaceuticals has received reimbursement approval from the Italian Medicines Agency (AIFA) for **AGAMREE® (vamorolone)**, a novel treatment for **Duc...
Santhera Pharmaceuticals has received approval from the Italian Medicines Agency (AIFA) for the reimbursement of **AGAMREE® (Vamorolon)** in the treatment of **...
Santhera Pharmaceuticals reported a **97% revenue increase** for 2025, driven largely by the global expansion of **AGAMREE® (vamorolone)** for treating Duchenne...
Santhera Pharmaceuticals has reported a **97% increase in total revenue** for 2025, driven by the strong market acceptance of **AGAMREE® (Vamorolon)**, a novel...
A new enzyme may enhance the effectiveness and longevity of medications like Ozempic for better diabetes and weight management.
The **King Faisal Specialist Hospital & Research Centre (KFSH)** will serve as a Silver Sponsor at the upcoming **Milken Institute Global Conference 2026** in B...
King Faisal Specialist Hospital & Research Centre (KFSH) is set to participate as a Silver Sponsor at the 2026 Milken Institute Global Conference in Beverly Hil...
Biomea Fusion has reported promising 52-week outcomes from its Phase 2 COVALENT-112 trial, evaluating **icovamenib** in patients with **type 1 diabetes (T1D)**....
Crinetics Pharmaceuticals has received European Commission approval for **PALSONIFY® (paltusotine)**, marking it as the first once-daily, oral therapy for treat...
Arbor Biotechnologies is set to present groundbreaking advancements in gene editing at the upcoming ASGCT 2026 Annual Meeting, showcasing a **novel compact reve...
Dyne Therapeutics has unveiled promising preclinical data demonstrating the **FORCE platform's** ability to effectively cross the **blood-brain barrier (BBB)**...
Umoja Biopharma has announced the acceptance of a poster presentation for its innovative **dual-targeted BCMA x GPRC5D in vivo CAR T cell therapy**, UB-VV500, a...
NurExone Biologic Inc. has secured a significant advancement in its biomanufacturing capabilities with the granting of Australian Patent No. 2020303456, which c...
Erasca, Inc. has reported promising preliminary results from its Phase 1 dose escalation trials for **ERAS-0015**, a pan-RAS molecular glue targeting RAS-mutant...
Aegis Treatment Centers has launched a new **Medication Unit** in Crescent City, California, enhancing local access to treatment for opioid use disorder (OUD) i...
Recent research highlights a compelling link between **air pollution exposure** and accelerated biological aging, particularly in relation to dementia risk. Thi...
Artificial intelligence (AI) is making significant strides in lung cancer therapeutics, with recent advancements yielding **85–95% accuracy** in biomarker ident...
